Shanghai Medicilon Inc (688202) - Total Assets
Based on the latest financial reports, Shanghai Medicilon Inc (688202) holds total assets worth CN¥2.77 Billion CNY (≈ $404.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688202 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Shanghai Medicilon Inc - Total Assets Trend (2016–2025)
This chart illustrates how Shanghai Medicilon Inc's total assets have evolved over time, based on quarterly financial data. Check 688202 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Shanghai Medicilon Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Medicilon Inc's total assets of CN¥2.77 Billion consist of 46.5% current assets and 53.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.9% |
| Accounts Receivable | CN¥408.31 Million | 15.6% |
| Inventory | CN¥112.22 Million | 4.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥269.20 Million | 10.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Shanghai Medicilon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shanghai Medicilon Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Medicilon Inc's current assets represent 46.5% of total assets in 2025, a decrease from 69.9% in 2016.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2025, down from 41.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 15.6% of total assets.
Shanghai Medicilon Inc Competitors by Total Assets
Key competitors of Shanghai Medicilon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
China | CN¥3.25 Billion |
Shanghai Medicilon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 2.76 | 3.69 |
| Quick Ratio | 1.72 | 2.60 | 3.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥651.54 Million | CN¥920.68 Million | CN¥509.62 Million |
Shanghai Medicilon Inc - Advanced Valuation Insights
This section examines the relationship between Shanghai Medicilon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.20 |
| Latest Market Cap to Assets Ratio | 0.43 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | CN¥2.62 Billion |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Medicilon Inc's assets below their book value (0.43x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Medicilon Inc's assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Medicilon Inc (2016–2025)
The table below shows the annual total assets of Shanghai Medicilon Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.62 Billion ≈ $383.69 Million |
-7.13% |
| 2024-12-31 | CN¥2.82 Billion ≈ $413.13 Million |
-13.55% |
| 2023-12-31 | CN¥3.27 Billion ≈ $477.90 Million |
+40.19% |
| 2022-12-31 | CN¥2.33 Billion ≈ $340.89 Million |
+29.89% |
| 2021-12-31 | CN¥1.79 Billion ≈ $262.46 Million |
+31.46% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.64 Million |
+20.92% |
| 2019-12-31 | CN¥1.13 Billion ≈ $165.11 Million |
+138.57% |
| 2018-12-31 | CN¥472.95 Million ≈ $69.21 Million |
+21.39% |
| 2017-12-31 | CN¥389.61 Million ≈ $57.01 Million |
+12.96% |
| 2016-12-31 | CN¥344.90 Million ≈ $50.47 Million |
-- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more